|
|
|
|
LEADER |
05040nam a2201429Ia 4500 |
001 |
10.1002-jcla.23769 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a A novel WT1 gene mutation in a chinese girl with denys-drash syndrome
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23769
|
520 |
3 |
|
|a Objective: Denys-Drash syndrome (DDS) is defined by the triad of Wilms tumor, nephrotic syndrome, and/or ambiguous genitalia. Genetic testing may help identify new gene mutation sites and play an important role in clinical decision-making. Methods: We present a patient with an XY karyotype and female appearance, nephropathy, and Wilms tumor in the right kidney. Genomic DNA was extracted from peripheral blood cells according to standard protocols. “Next-generation” sequencing (NGS) was performed to identify novel variants. The variant was analyzed with Mutation Taster, and its function was explored by a cell growth inhibition assay. Results: We found the first case of Denys-Drash syndrome with the uncommon missense mutation (c.1420C>T, p.His474 Tyr) in the WT1 gene. In silico analysis, the variant was predicted “disease-causing” by Mutation Taster. The mutated variant showed a weaker effect in inhibiting tumor cells than wild-type WT1. Conclusions: The uncommon missense mutation (c.1420C>T, p.His474 Tyr) in the WT1 gene may be a crucial marker in DDS. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a 46
|
650 |
0 |
4 |
|a abdominal mass
|
650 |
0 |
4 |
|a abdominal radiography
|
650 |
0 |
4 |
|a albumin
|
650 |
0 |
4 |
|a albumin blood level
|
650 |
0 |
4 |
|a amino acid sequence
|
650 |
0 |
4 |
|a Amino Acid Sequence
|
650 |
0 |
4 |
|a antineoplastic agent
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a Asian continental ancestry group
|
650 |
0 |
4 |
|a Asian Continental Ancestry Group
|
650 |
0 |
4 |
|a B scan
|
650 |
0 |
4 |
|a Base Sequence
|
650 |
0 |
4 |
|a CA 19-9 antigen
|
650 |
0 |
4 |
|a carcinoembryonic antigen
|
650 |
0 |
4 |
|a carcinogenesis
|
650 |
0 |
4 |
|a case report
|
650 |
0 |
4 |
|a Cell Line, Tumor
|
650 |
0 |
4 |
|a cell viability
|
650 |
0 |
4 |
|a chemistry
|
650 |
0 |
4 |
|a child
|
650 |
0 |
4 |
|a China
|
650 |
0 |
4 |
|a China
|
650 |
0 |
4 |
|a Chinese
|
650 |
0 |
4 |
|a clinical article
|
650 |
0 |
4 |
|a clinical examination
|
650 |
0 |
4 |
|a clitoris hypertrophy
|
650 |
0 |
4 |
|a complementary DNA
|
650 |
0 |
4 |
|a computer assisted tomography
|
650 |
0 |
4 |
|a computer simulation
|
650 |
0 |
4 |
|a Computer Simulation
|
650 |
0 |
4 |
|a contrast enhancement
|
650 |
0 |
4 |
|a Denys Drash syndrome
|
650 |
0 |
4 |
|a Denys Drash syndrome
|
650 |
0 |
4 |
|a Denys-Drash Syndrome
|
650 |
0 |
4 |
|a Denys-Drash syndrome (DDS)
|
650 |
0 |
4 |
|a diagnostic imaging
|
650 |
0 |
4 |
|a disease severity
|
650 |
0 |
4 |
|a DNA extraction
|
650 |
0 |
4 |
|a DNA sequence
|
650 |
0 |
4 |
|a electrocardiogram
|
650 |
0 |
4 |
|a enalapril maleate
|
650 |
0 |
4 |
|a exon
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a follow up
|
650 |
0 |
4 |
|a Follow-Up Studies
|
650 |
0 |
4 |
|a genetic screening
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a genomic DNA
|
650 |
0 |
4 |
|a heterozygosity
|
650 |
0 |
4 |
|a high throughput sequencing
|
650 |
0 |
4 |
|a histopathology
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human tissue
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a hypertension
|
650 |
0 |
4 |
|a image analysis
|
650 |
0 |
4 |
|a indel mutation
|
650 |
0 |
4 |
|a infant
|
650 |
0 |
4 |
|a Infant
|
650 |
0 |
4 |
|a karyotype
|
650 |
0 |
4 |
|a kidney biopsy
|
650 |
0 |
4 |
|a kidney disease
|
650 |
0 |
4 |
|a laboratory test
|
650 |
0 |
4 |
|a laparoscopy
|
650 |
0 |
4 |
|a Laparoscopy
|
650 |
0 |
4 |
|a large core needle biopsy
|
650 |
0 |
4 |
|a microalbuminuria
|
650 |
0 |
4 |
|a missense mutation
|
650 |
0 |
4 |
|a mutation
|
650 |
0 |
4 |
|a Mutation
|
650 |
0 |
4 |
|a nephrectomy
|
650 |
0 |
4 |
|a nephroblastoma
|
650 |
0 |
4 |
|a nephroblastoma
|
650 |
0 |
4 |
|a nephrotic syndrome
|
650 |
0 |
4 |
|a nucleotide sequence
|
650 |
0 |
4 |
|a pedigree
|
650 |
0 |
4 |
|a Pedigree
|
650 |
0 |
4 |
|a physical examination
|
650 |
0 |
4 |
|a preschool child
|
650 |
0 |
4 |
|a RNA extraction
|
650 |
0 |
4 |
|a Sanger sequencing
|
650 |
0 |
4 |
|a sequence alignment
|
650 |
0 |
4 |
|a single nucleotide polymorphism
|
650 |
0 |
4 |
|a Tomography, X-Ray Computed
|
650 |
0 |
4 |
|a tumor cell line
|
650 |
0 |
4 |
|a valsartan
|
650 |
0 |
4 |
|a Wilms tumor
|
650 |
0 |
4 |
|a Wilms Tumor
|
650 |
0 |
4 |
|a Wilms tumor-1 (WT1)
|
650 |
0 |
4 |
|a WT1 gene
|
650 |
0 |
4 |
|a WT1 protein
|
650 |
0 |
4 |
|a WT1 protein
|
650 |
0 |
4 |
|a WT1 protein, human
|
650 |
0 |
4 |
|a WT1 Proteins
|
650 |
0 |
4 |
|a x-ray computed tomography
|
650 |
0 |
4 |
|a XY karyotype
|
700 |
1 |
|
|a Cai, J.
|e author
|
700 |
1 |
|
|a Guan, Z.
|e author
|
700 |
1 |
|
|a He, M.
|e author
|
700 |
1 |
|
|a Jin, H.
|e author
|
700 |
1 |
|
|a Li, L.
|e author
|
700 |
1 |
|
|a Mao, J.
|e author
|
700 |
1 |
|
|a Shu, Q.
|e author
|
700 |
1 |
|
|a Wang, F.
|e author
|
700 |
1 |
|
|a Wang, J.
|e author
|
700 |
1 |
|
|a Zhao, M.
|e author
|
700 |
1 |
|
|a Zhu, K.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|